Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315734 | 0.90 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL6312676 | 0.89 | EDNRB (0.80) | EDNRBEDNRA | |
| SCHEMBL8900846 | 0.88 | EDNRA (0.81) | EDNRBEDNRA | |
| SCHEMBL8798982 | 0.88 | EDNRB (0.78) | EDNRBEDNRA | |
| SCHEMBL6315635 | 0.87 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8902335 | 0.83 | EDNRB (0.80) | EDNRBEDNRA | |
| SCHEMBL6315259 | 0.82 | EDNRB (0.77) | EDNRBEDNRA | |
| SCHEMBL6321016 | 0.82 | EDNRB (0.77) | EDNRBEDNRA | |
| SCHEMBL8578754 | 0.81 | EDNRB (0.83) | EDNRBEDNRA | |
| SCHEMBL8901534 | 0.81 | EDNRB (0.69) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1585636-A | Use of endothelin receptor antagonists in the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-02-23 | — | — | CN | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-0757039-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-05 | — | — | EP | claimed |
| CN-1585636-A | Use of endothelin receptor antagonists in the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-02-23 | — | — | CN | disclosed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.